OGT 2599

Drug Profile

OGT 2599

Latest Information Update: 12 Dec 2003

Price : $50

At a glance

  • Originator Celltech Group
  • Class Antifungals
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 12 Dec 2003 Discontinued - Preclinical for Mycoses in United Kingdom (unspecified route)
  • 08 Dec 2003 The integration of Oxford GlycoSciences into Celltech Group has been completed
  • 31 Jul 2003 Oxford GlycoSciences has been acquired by Celltech Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top